Clinical Trials

The purpose of this study is to non-invasively characterize the fibrotic consequences of single ventricle physiology, its possible solution and effect on lymphatics. This project investigates the response to acute imposition of Fontan hemodynamics by examining the interrelationship between liver and cardiac fibrosis/dysfunction and lymphatic congestion along with a pilot trial of the antifibrotic agent, spironolactone, to prevent these consequences and to determine if MRI can discern these differences. The combination of serum biomarkers and MRI form a powerful non-invasive tool in putting together this complicated web of dysfunction.

This project will determine the health impact of parenthood on people with cystic fibrosis (CF). The study team will use retrospective data to provide relatively immediate evidence on parenthood's effect on pulmonary health.

Do you want to participate in a study with your child who has cystic fibrosis? This study is exploring computer models to compare cell samples from the noses of people who have cystic fibrosis, their parents, and other healthy individuals in hopes of better predicting how patients will respond to medicine. These computer models may allow medicines to be developed more rapidly and better predict who will respond to a certain cystic fibrosis treatment. To participate in this study, you must fall into one of the following groups: (1) have cystic fibrosis and be at least 12 years old, (2) be the biological parent of a cystic fibrosis patient enrolled in the study and be at least 18 years old, or (3) have no history of lung disease and be at least 18 years old. This study is located in Pittsburgh, Pennsylvania.

Are you at least 18 years old and have heart failure? Researchers in this clinical trial are testing whether a new type of hormone therapy may help with symptoms and quality of life for people who have heart failure. Participants will take medication by mouth daily. The study is taking place in Philadelphia, Pennsylvania.

Do you want to help find new treatments for heart failure with preserved ejection fraction? This study is testing whether a medicine called spironolactone can help treat heart failure with preserved ejection fraction when paired with the standard treatment. Spironolactone helps to remove excess water and sodium from the body. To participate in this study, you must be between 50 and 99 years old and diagnosed with heart failure with preserved ejection fraction.

Do you have heart failure with reduced ejection fraction and thyroid problems? This study will test whether hormone therapy with liothyronine is safe and effective for treating people who have heart failure with reduced ejection fraction and low triiothyronine (T3) syndrome. Low T3 syndrome is a type of thyroid hormone that helps control many functions of your body. To participate in this study, you must be at least 18 years old and diagnosed with heart failure with reduced ejection fraction. This study is located in Philadelphia, Pennsylvania.

Do you have heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter defibrillator (ICD)? This study is testing the effectiveness of thyroid hormone therapy with a medicine called liothyronine (LT3) in individuals HFrEF. To participate in this study, you must be at least 18 years old and have Class I, II, or III heart failure. This study takes place in Philadelphia, Pennsylvania.

Do you have heart failure with preserved ejection fraction (HFPEF)? This study is testing the efficacy of a diuretic medicine called spironolactone that stops your body from absorbing too much salt and keeps your potassium levels from dropping too low. Participants of this study must be between 50 and 99 years old and already taking diuretic medicine. This study takes place in multiple locations across the United States and Sweden.